PTC Therapeutics, Inc. Revenue from Contract with Customer, Including Assessed Tax
PTC Therapeutics, Inc. (PTCT) reported Revenue from Contract with Customer, Including Assessed Tax of $75.24 million for the 3-month period ending 2020-06-30, per its 10-Q filed 2020-08-05.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2020-08-05
- PTC Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2020-06-30 was $75.24M, a 12.02% decline year-over-year.
- PTC Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2020-03-31 was $68.26M, a 27.39% increase year-over-year.
- PTC Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2019-12-31 was $96.46M, a 12.38% increase year-over-year.
- PTC Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2019-09-30 was $71.42M, a 33.26% increase year-over-year.
- PTC Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2019 was $306.98M, a 15.96% increase from fiscal 2018.
- PTC Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2018 was $264.73M, a 36.19% increase from fiscal 2017.
- PTC Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2017 was $194.39M, a 135.04% increase from fiscal 2016.
- PTC Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2016 was $82.70M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|---|
| 2020-06-30 | $75.24M 10-Q · filed 2020-08-05 | $143.50M 10-Q · filed 2020-08-05 | $239.96M derived: sum of 3 quarters · filed 2020-08-05 | $311.37M derived: sum of 4 quarters · filed 2020-08-05 | |
| 2020-03-31 | $68.26M 10-Q · filed 2020-04-30 | $164.72M derived: sum of 2 quarters · filed 2020-04-30 | $236.13M derived: sum of 3 quarters · filed 2020-04-30 | $321.66M derived: sum of 4 quarters · filed 2020-08-05 | |
| 2019-12-31 | $96.46M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $167.88M derived: sum of 2 quarters · filed 2020-03-02 | $253.40M derived: sum of 3 quarters · filed 2020-08-05 | $306.98M 10-K · filed 2020-03-02 | |
| 2019-09-30 | $71.42M 10-Q · filed 2019-10-30 | $156.94M derived: sum of 2 quarters · filed 2020-08-05 | $210.52M 10-Q · filed 2019-10-30 | $296.35M derived: sum of 4 quarters · filed 2020-08-05 | |
| 2019-06-30 | $85.52M 10-Q · filed 2020-08-05 | $139.10M 10-Q · filed 2020-08-05 | $224.94M derived: sum of 3 quarters · filed 2020-08-05 | $278.53M derived: sum of 4 quarters · filed 2020-08-05 | |
| 2019-03-31 | $53.58M 10-Q · filed 2020-04-30 | $139.42M derived: sum of 2 quarters · filed 2020-04-30 | $193.01M derived: sum of 3 quarters · filed 2020-04-30 | $261.75M derived: sum of 4 quarters · filed 2020-04-30 | |
| 2018-12-31 | $85.83M 10-K · filed 2019-03-01 | $139.42M derived: sum of 2 quarters · filed 2019-10-30 | $208.17M derived: sum of 3 quarters · filed 2019-10-30 | $264.73M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $53.59M 10-Q · filed 2019-10-30 | $122.33M derived: sum of 2 quarters · filed 2019-10-30 | $178.40M 10-Q · filed 2019-10-30 | $236.35M derived: sum of 4 quarters · filed 2019-10-30 | |
| 2018-06-30 | $68.74M 10-Q · filed 2019-08-06 | $124.81M 10-Q · filed 2019-08-06 | $182.76M derived: sum of 3 quarters · filed 2019-08-06 | $224.54M derived: sum of 4 quarters · filed 2019-08-06 | |
| 2018-03-31 | $56.06M 10-Q · filed 2019-05-02 | $55.98M 10-K · filed 2019-03-01 | $114.02M derived: sum of 2 quarters · filed 2019-05-02 | $155.79M derived: sum of 3 quarters · filed 2019-05-02 | $203.69M derived: sum of 4 quarters · filed 2019-05-02 |
| 2017-12-31 | $57.95M 10-K · filed 2019-03-01 | $99.73M derived: sum of 2 quarters · filed 2019-03-01 | $147.62M derived: sum of 3 quarters · filed 2019-03-01 | $194.39M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $41.78M 10-K · filed 2019-03-01 | $41.85M 10-Q · filed 2018-11-05 | $89.67M derived: sum of 2 quarters · filed 2019-03-01 | $116.36M 10-Q · filed 2018-11-05 | |
| 2017-06-30 | $47.89M 10-K · filed 2019-03-01 | $47.96M 10-Q · filed 2018-08-07 | $74.51M 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | $26.44M 10-K · filed 2019-03-01 | ||||
| 2016-12-31 | $82.70M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |